Literature DB >> 6166544

Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor.

M R Daha, L A Van Es.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6166544      PMCID： PMC1555189     

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


× No keyword cloud information.
  17 in total

1.  Activation of the classical pathway of complement by the C3NeF-stabilized cell-bound amplification convertase.

Authors:  M R Daha; L A van Es
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

2.  Serum C'3 lytic system in patients with glomerulonephritis.

Authors:  R E Spitzer; E H Vallota; J Forristal; E Sudora; A Stitzel; N C Davis; C D West
Journal:  Science       Date:  1969-04-25       Impact factor: 47.728

3.  Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3).

Authors:  L G Hunsicker; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

4.  Lactoperoxidase coupled to polyacrylamide for radio-iodination of proteins to high specific activity.

Authors:  J I Thorell; I Larsson
Journal:  Immunochemistry       Date:  1974-04

5.  Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme.

Authors:  L Halbwachs; M Leveillé; P Lesavre; S Wattel; J Leibowitch
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

6.  Isolation and characterization of rat complement factor B and its interaction with cell-bound human C3.

Authors:  M R Daha; L A van Es
Journal:  Immunology       Date:  1980-12       Impact factor: 7.397

7.  Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; L A Vanes; A Cats
Journal:  Immunology       Date:  1980-07       Impact factor: 7.397

8.  Further evidence for the antibody nature of C3 nephritic factor (C3NeF).

Authors:  M R Daha; L A van Es
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

9.  A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.

Authors:  E H Vallota; O Götze; H L Spiegelberg; J Forristal; C D West; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

10.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307
View more
  14 in total

1.  Detection of Complement Factor B Autoantibodies by ELISA.

Authors:  Mihály Józsi; Barbara Uzonyi
Journal:  Methods Mol Biol       Date:  2021

Review 2.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

3.  MPGN II--genetically determined by defective complement regulation?

Authors:  Christoph Licht; Ursula Schlötzer-Schrehardt; Michael Kirschfink; Peter F Zipfel; Bernd Hoppe
Journal:  Pediatr Nephrol       Date:  2006-09-23       Impact factor: 3.714

Review 4.  Dense deposit disease.

Authors:  Richard J H Smith; Claire L Harris; Matthew C Pickering
Journal:  Mol Immunol       Date:  2011-05-24       Impact factor: 4.407

5.  Causes of alternative pathway dysregulation in dense deposit disease.

Authors:  Yuzhou Zhang; Nicole C Meyer; Kai Wang; Carla Nishimura; Kathy Frees; Michael Jones; Louis M Katz; Sanjeev Sethi; Richard J H Smith
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-05       Impact factor: 8.237

6.  Heterogeneity, polypeptide chain composition and antigenic reactivity of autoantibodies (F-42) that are directed against the classical pathway C3 convertase of complement and isolated from sera of patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; L A van Es
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

7.  Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN).

Authors:  H Ohi; S Watanabe; T Fujita; T Yasugi
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

Review 8.  The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease.

Authors:  Federica Defendi; Nicole M Thielens; Giovanna Clavarino; Jean-Yves Cesbron; Chantal Dumestre-Pérard
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

Review 9.  Complement components and their autoantibodies.

Authors:  P Norsworthy; K A Davies
Journal:  Mol Biotechnol       Date:  2003-03       Impact factor: 2.860

10.  Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.

Authors:  Danielle Paixão-Cavalcante; Margarita López-Trascasa; Lillemor Skattum; Patricia C Giclas; Timothy H Goodship; Santiago Rodríguez de Córdoba; Lennart Truedsson; B Paul Morgan; Claire L Harris
Journal:  Kidney Int       Date:  2012-08-01       Impact factor: 10.612
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.